International commercial law firm Hill Dickinson has advised Juvenescence Ltd on its multimillion pound joint venture with Insilico Medicine Inc.

Juvenescence is an investment company focused on developing therapies to increase human longevity. Its principals, Jim Mellon, Dr. Greg Bailey and Dr. Declan Doogan, have extensive track records in drug development, company formation, and biotech investment. The company creates new ventures and invests directly in both startup and established longevity related companies.

Insilico Medicine develops artificial intelligence for drug discovery and biomarker development. Based in Baltimore, it also has R&D centres in the UK, Belgium and Russia.

The new joint venture, Juvenescence AI, will focus on advancing a pipeline of new compounds licensed from Insilico Medicine with the aim of developing therapies for the ageing process as well as age-related diseases such as diabetes, dementia, cancer, respiratory disease and cardiovascular disease.

Juvenescence made an undisclosed investment into Insilico Medicine simultaneously with the creation of the joint venture.

Hill Dickinson’s Michael Corcoran and Rajveer Sehmi advised Juvenescence on the deal, including the terms of the joint venture, funding structure and due diligence.